Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations

Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations

Our research team has synthesized 33 tricyclic pyrazolopyrimidine arylidene ester derivatives using the lead compound CAM551 as a starting point. This was achieved by a designed five‐step synthesis strategy. The synthesized compounds' inhibitory activities against HT‐116 human colorectal adenoc...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of heterocyclic chemistry 2024-04, Vol.61 (4), p.651-668
Hauptverfasser: Lu, Tong, Nie, Lifei, Tang, Dan, Bozorov, Khurshed, Zhao, Jiangyu, Aisa, Haji Akber
Format: Artikel
Sprache:eng
Schlagworte:
Cancer
Lead compounds
Molecular docking
Pyrazolopyrimidines
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 668
container_issue 4
container_start_page 651
container_title Journal of heterocyclic chemistry
container_volume 61
creator Lu, Tong
Nie, Lifei
Tang, Dan
Bozorov, Khurshed
Zhao, Jiangyu
Aisa, Haji Akber
description Our research team has synthesized 33 tricyclic pyrazolopyrimidine arylidene ester derivatives using the lead compound CAM551 as a starting point. This was achieved by a designed five‐step synthesis strategy. The synthesized compounds' inhibitory activities against HT‐116 human colorectal adenocarcinoma cell line and HGC27 human gastric cancer cells were assessed through traditional MTT assays. The designed and synthesized compounds demonstrated superior inhibition against both types of cancer cells. Additionally, compound 7b, which contains a long‐chain substituent, exhibited improved inhibition against hepatocellular carcinoma cells and a greater safety profile. These findings indicate that compound 7b has the potential as an antitumor lead compound for future research. Research basis and work of this paper.
doi_str_mv 10.1002/jhet.4791
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_3031439799</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3031439799</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2571-8d8fdf56dc3683c3094984beab272fe4e109c830213f1887c4890bb213587a203</originalsourceid><addsrcrecordid>eNp1kMFPwyAUxonRxDk9-B-QePLQDUo74GiW6TRLPDgTb4TSV8fsyoRuWv3npc6rp8eD3_se34fQJSUjSkg6Xq-gHWVc0iM0oDJjSU4lO0aD-JYmNE9fTtFZCOvYUsb5AH0_dU27gmADdhVuvTWdqa3B287rL1e7WO3GlrYBrH1X2xLiCUILHpfg7V63dg8B66bEUcZ6bLrWte4zSvR3G1eD2dU60s682eYVw17XuzjlmnCOTipdB7j4q0P0fDtbTufJ4vHufnqzSEyac5qIUlRllU9KwyaCGUZkJkVWgC5SnlaQASXSCNY7qqgQ3GRCkqKIbS64TgkboquD7ta79138vFq7nW_iSsUIoxmTXMpIXR8o410IHiq1jdajaUWJ6rNVfbaqzzay4wP7YWvo_gfVw3y2_J34AQ4Pfrg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3031439799</pqid></control><display><type>article</type><title>Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Lu, Tong ; Nie, Lifei ; Tang, Dan ; Bozorov, Khurshed ; Zhao, Jiangyu ; Aisa, Haji Akber</creator><creatorcontrib>Lu, Tong ; Nie, Lifei ; Tang, Dan ; Bozorov, Khurshed ; Zhao, Jiangyu ; Aisa, Haji Akber</creatorcontrib><description>Our research team has synthesized 33 tricyclic pyrazolopyrimidine arylidene ester derivatives using the lead compound CAM551 as a starting point. This was achieved by a designed five‐step synthesis strategy. The synthesized compounds' inhibitory activities against HT‐116 human colorectal adenocarcinoma cell line and HGC27 human gastric cancer cells were assessed through traditional MTT assays. The designed and synthesized compounds demonstrated superior inhibition against both types of cancer cells. Additionally, compound 7b, which contains a long‐chain substituent, exhibited improved inhibition against hepatocellular carcinoma cells and a greater safety profile. These findings indicate that compound 7b has the potential as an antitumor lead compound for future research. Research basis and work of this paper.</description><identifier>ISSN: 0022-152X</identifier><identifier>EISSN: 1943-5193</identifier><identifier>DOI: 10.1002/jhet.4791</identifier><language>eng</language><publisher>Chichester, UK: John Wiley &amp; Sons, Inc</publisher><subject>Cancer ; Lead compounds ; Molecular docking ; Pyrazolopyrimidines</subject><ispartof>Journal of heterocyclic chemistry, 2024-04, Vol.61 (4), p.651-668</ispartof><rights>2024 Wiley Periodicals LLC.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2571-8d8fdf56dc3683c3094984beab272fe4e109c830213f1887c4890bb213587a203</cites><orcidid>0000-0003-4652-6879</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjhet.4791$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjhet.4791$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids></links><search><creatorcontrib>Lu, Tong</creatorcontrib><creatorcontrib>Nie, Lifei</creatorcontrib><creatorcontrib>Tang, Dan</creatorcontrib><creatorcontrib>Bozorov, Khurshed</creatorcontrib><creatorcontrib>Zhao, Jiangyu</creatorcontrib><creatorcontrib>Aisa, Haji Akber</creatorcontrib><title>Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations</title><title>Journal of heterocyclic chemistry</title><description>Our research team has synthesized 33 tricyclic pyrazolopyrimidine arylidene ester derivatives using the lead compound CAM551 as a starting point. This was achieved by a designed five‐step synthesis strategy. The synthesized compounds' inhibitory activities against HT‐116 human colorectal adenocarcinoma cell line and HGC27 human gastric cancer cells were assessed through traditional MTT assays. The designed and synthesized compounds demonstrated superior inhibition against both types of cancer cells. Additionally, compound 7b, which contains a long‐chain substituent, exhibited improved inhibition against hepatocellular carcinoma cells and a greater safety profile. These findings indicate that compound 7b has the potential as an antitumor lead compound for future research. Research basis and work of this paper.</description><subject>Cancer</subject><subject>Lead compounds</subject><subject>Molecular docking</subject><subject>Pyrazolopyrimidines</subject><issn>0022-152X</issn><issn>1943-5193</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp1kMFPwyAUxonRxDk9-B-QePLQDUo74GiW6TRLPDgTb4TSV8fsyoRuWv3npc6rp8eD3_se34fQJSUjSkg6Xq-gHWVc0iM0oDJjSU4lO0aD-JYmNE9fTtFZCOvYUsb5AH0_dU27gmADdhVuvTWdqa3B287rL1e7WO3GlrYBrH1X2xLiCUILHpfg7V63dg8B66bEUcZ6bLrWte4zSvR3G1eD2dU60s682eYVw17XuzjlmnCOTipdB7j4q0P0fDtbTufJ4vHufnqzSEyac5qIUlRllU9KwyaCGUZkJkVWgC5SnlaQASXSCNY7qqgQ3GRCkqKIbS64TgkboquD7ta79138vFq7nW_iSsUIoxmTXMpIXR8o410IHiq1jdajaUWJ6rNVfbaqzzay4wP7YWvo_gfVw3y2_J34AQ4Pfrg</recordid><startdate>202404</startdate><enddate>202404</enddate><creator>Lu, Tong</creator><creator>Nie, Lifei</creator><creator>Tang, Dan</creator><creator>Bozorov, Khurshed</creator><creator>Zhao, Jiangyu</creator><creator>Aisa, Haji Akber</creator><general>John Wiley &amp; Sons, Inc</general><general>Wiley Subscription Services, Inc</general><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0003-4652-6879</orcidid></search><sort><creationdate>202404</creationdate><title>Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations</title><author>Lu, Tong ; Nie, Lifei ; Tang, Dan ; Bozorov, Khurshed ; Zhao, Jiangyu ; Aisa, Haji Akber</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2571-8d8fdf56dc3683c3094984beab272fe4e109c830213f1887c4890bb213587a203</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Cancer</topic><topic>Lead compounds</topic><topic>Molecular docking</topic><topic>Pyrazolopyrimidines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Tong</creatorcontrib><creatorcontrib>Nie, Lifei</creatorcontrib><creatorcontrib>Tang, Dan</creatorcontrib><creatorcontrib>Bozorov, Khurshed</creatorcontrib><creatorcontrib>Zhao, Jiangyu</creatorcontrib><creatorcontrib>Aisa, Haji Akber</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of heterocyclic chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Tong</au><au>Nie, Lifei</au><au>Tang, Dan</au><au>Bozorov, Khurshed</au><au>Zhao, Jiangyu</au><au>Aisa, Haji Akber</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations</atitle><jtitle>Journal of heterocyclic chemistry</jtitle><date>2024-04</date><risdate>2024</risdate><volume>61</volume><issue>4</issue><spage>651</spage><epage>668</epage><pages>651-668</pages><issn>0022-152X</issn><eissn>1943-5193</eissn><abstract>Our research team has synthesized 33 tricyclic pyrazolopyrimidine arylidene ester derivatives using the lead compound CAM551 as a starting point. This was achieved by a designed five‐step synthesis strategy. The synthesized compounds' inhibitory activities against HT‐116 human colorectal adenocarcinoma cell line and HGC27 human gastric cancer cells were assessed through traditional MTT assays. The designed and synthesized compounds demonstrated superior inhibition against both types of cancer cells. Additionally, compound 7b, which contains a long‐chain substituent, exhibited improved inhibition against hepatocellular carcinoma cells and a greater safety profile. These findings indicate that compound 7b has the potential as an antitumor lead compound for future research. Research basis and work of this paper.</abstract><cop>Chichester, UK</cop><pub>John Wiley &amp; Sons, Inc</pub><doi>10.1002/jhet.4791</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0003-4652-6879</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0022-152X
ispartof Journal of heterocyclic chemistry, 2024-04, Vol.61 (4), p.651-668
issn 0022-152X
1943-5193
language eng
recordid cdi_proquest_journals_3031439799
source Wiley Online Library Journals Frontfile Complete
subjects Cancer
Lead compounds
Molecular docking
Pyrazolopyrimidines
title Synthesis of tricyclic pyrazolopyrimidine arylidene ester derivatives and their cytotoxic and molecular docking evaluations
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T19%3A44%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Synthesis%20of%20tricyclic%20pyrazolopyrimidine%20arylidene%20ester%20derivatives%20and%20their%20cytotoxic%20and%20molecular%20docking%20evaluations&rft.jtitle=Journal%20of%20heterocyclic%20chemistry&rft.au=Lu,%20Tong&rft.date=2024-04&rft.volume=61&rft.issue=4&rft.spage=651&rft.epage=668&rft.pages=651-668&rft.issn=0022-152X&rft.eissn=1943-5193&rft_id=info:doi/10.1002/jhet.4791&rft_dat=%3Cproquest_cross%3E3031439799%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3031439799&rft_id=info:pmid/&rfr_iscdi=true